

# Steve Lu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6320332/publications.pdf>

Version: 2024-02-01

8  
papers

5,810  
citations

1478505

6  
h-index

1720034

7  
g-index

8  
all docs

8  
docs citations

8  
times ranked

11107  
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. <i>Cancer Cell</i> , 2021, 39, 96-108.e6.	16.8	153
2	CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors. <i>Cancer Discovery</i> , 2021, 11, 1844-1859.	9.4	37
3	The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors. <i>New England Journal of Medicine</i> , 2021, 384, 1168-1170.	27.0	137
4	Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies—Reply. <i>JAMA Oncology</i> , 2020, 6, 299.	7.1	1
5	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 1195.	7.1	431
6	Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates. , 2019, 7, 123.		2
7	Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 7024-7034.	7.0	104
8	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	12.6	4,945